Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 1

Review Article

Valerian: No Evidence for Clinically Relevant Interactions

Table 1

Potential pharmacokinetic interactions of valerian according to the published literature. The conclusions by the respective authors, the ratings given by MedIQ (http://www.mediq.ch, a Swiss independent interaction data base, which is structured according to mechanisms of interaction and includes herbal drugs), and the conclusions regarding the potential of clinically relevant interactions based on a critical analysis of the published studies are reported.

Metabolic pathwayIn vitro studiesIn vivo studiesInteraction potential (according to medIQ database [33])Indication for a clinically relevant interaction

CYP 1A2No effect [34]No effect [35]None

CYP 2D6Induction [36]No effect [35, 37]Weak inhibitorNone

CYP 2E1No effect [35]None

CYP 3A4Induction [36, 38]No effect [34, 35, 37]Weak inductorNone

P-glycoprotein Weak inhibition? [39, 40]No data availableWeak inhibitorNone

UGT 1A1Weak inhibition? [41, 42]No data availableWeak inhibitorNone

UGT 2B7Weak inhibition? [41]No data availableWeak inhibitorNone

CYP: cytochrome P450; UGT: uridine 5′-diphosphate glucuronosyltransferase.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.